Your browser doesn't support javascript.
loading
Percutaneous tibial neuromodulation initial therapy compliance and subsequent third-line treatment patterns.
Padmanabhan, Priya; Zwaans, Bernadette M M; Wu, Charlotte; Boldt, Ryan J.
Afiliación
  • Padmanabhan P; Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Zwaans BMM; Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Wu C; Medtronic Plc, Minneapolis, MN, USA.
  • Boldt RJ; Medtronic Plc, Minneapolis, MN, USA.
Neurourol Urodyn ; 43(5): 1157-1170, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38587245
ABSTRACT

PURPOSE:

Percutaneous Tibial Neuromodulation (PTNM) is used to treat Overactive Bladder (OAB). This analysis summarizes patient adherence to PTNM treatment and examines trends of other third-line therapy use during and after PTNM.

METHODS:

Optum's deidentified Clinformatics® Data Mart Database (CDM) and CMS Research Identifiable Files were queried for adults with OAB symptoms and who underwent PTNM treatment (2019-2020). We evaluated the proportion of patients who completed 12 visits within 1 year, and defined patients as treatment compliant if 12 PTNM visits were completed within 12 weeks. We then identified the proportion of patients who used other third-line therapies after PTNM and stratified these patients based on their PTNM therapy compliance status.

RESULTS:

2302 patients met selection criteria from CDM and 16,473 patients from CMS. The proportion of patients completing a full PTNM treatment course increased over time; from 16% at week 12% to 42% by week 52 (CDM) and 24% to 38% (CMS). Other third-line therapy use increased over time and was higher for PTNM noncompliant versus compliant patients at 52 weeks onabotulinumtoxinA was 6.5% versus 5.7% for noncompliant versus compliant (CMS, p = 0.0661) and 6.4% versus 4.9% (CDM, p = 0.035), SNM trial procedure was 6.5% versus 2.5% (CDM, p = 0.002) and 4.2% versus 2.0% (CMS, p = 0.010).

CONCLUSIONS:

Most patients are noncompliant with recommended PTNM treatment regimen. Albeit low, third-line therapy was pursued more frequently by noncompliant patients. Given low compliance, the effectiveness of PTNM may be compromised. Alternative implantable technologies may be needed to assure effectiveness of neuromodulation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nervio Tibial / Estimulación Eléctrica Transcutánea del Nervio / Cooperación del Paciente / Vejiga Urinaria Hiperactiva Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neurourol Urodyn Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nervio Tibial / Estimulación Eléctrica Transcutánea del Nervio / Cooperación del Paciente / Vejiga Urinaria Hiperactiva Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neurourol Urodyn Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos